Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
70 hedge funds and large institutions have $89.1M invested in Regulus Therapeutics in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 8 closing their positions.
124% more call options, than puts
Call options by funds: $195K | Put options by funds: $87K
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
11% more funds holding
Funds holding: 63 → 70 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.03% less ownership
Funds ownership: 93.68% → 86.65% (-7%)
19% less capital invested
Capital invested by funds: $109M → $89.1M (-$20.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.53M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.48M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$537K |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$500K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$215K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.07M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.8M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.56M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$588K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$446K |
RGLS Hedge Fund Activity: Q3 2024 in Review
70 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2024, worth a combined $89.1M — down 19% from $109M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RGLS positions and 8 closed out — a net gain of 8 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $3.53M. The largest seller was RA Capital Management, cutting an estimated $9.07M.
- 70 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2024, up from 63 in Q2 2024.
- Funds reported $89.1M of Regulus Therapeutics stock for Q3 2024, down 19% quarter-over-quarter.
- 16 funds opened new Regulus Therapeutics positions in Q3 2024 and 8 closed out, a net change of +8 holders.
- The largest Regulus Therapeutics buyer in Q3 2024 was T. Rowe Price Associates, an estimated $3.53M added.
- The largest Regulus Therapeutics seller in Q3 2024 was RA Capital Management, an estimated $9.07M sold.
Based on aggregated 13F filings for Q3 2024.